|Health - Second Report|
Here you can browse the report together with the Proceedings of the Committee. The published report was ordered by the House of Commons to be printed 20 June 2002.
Terms of Reference
I. IS NICE PROVIDING CLEAR AND CREDIBLE GUIDANCE?
II. HAS NICE ENDED CONFUSION BY PROVIDING
A SINGLE NATIONAL FOCUS?
Confusion between NICE guidance and guidance
issued by other bodies
Confusion about NICE's own guidance
Confusion between technology appraisals and
The timing of NICE guidance, 'NICE blight',
and confusion and duplication within local health economies
Status of NICE guidance
III. IS NICE PROVIDING GUIDANCE THAT IS LOCALLY
OWNED AND ACTED ON IN THE RIGHT WAY
Securing local ownership
Has NICE guidance been acted on in the right
way and been implemented fully?
Mandatory implementation of NICE's recommendations
IV. IS NICE ACTIVELY PROMOTING INTERVENTIONS
WITH GOOD EVIDENCE OF CLINICAL AND COST-EFFECTIVENESS SO THAT
PATIENTS HAVE FASTER ACCESS TO TREATMENTS KNOWN TO WORK?
Faster access for patients?
The issue of evidence and technical quality
Quality of evidence
Quality of NICE's analysis
How does NICE arrive at its decisions?
Cost-effectiveness and affordability
NICE's relationship with the pharmaceutical
Independence from government and selection
The topic selection process
NICE's current topic focus
Beta interferon and independence
The wider prioritisation debate
The quality and credibility of NICE's work
The focus, organisation and implementation
of NICE's work
NICE in its wider context
LIST OF CONCLUSIONS AND RECOMMENDATIONS
ANNEX - BACKGROUND
How NICE works
LIST OF ABBREVIATIONS
PROCEEDINGS OF THE COMMITTEE RELATING TO
LIST OF WITNESSES
LIST OF MEMORANDA INCLUDED IN THE MINUTES
LIST OF APPENDICES TO THE MINUTES OF EVIDENCE
LIST OF UNPRINTED MEMORANDA
MINUTES OF EVIDENCE - VOLUME II (HC 515-II)
APPENDICES TO THE MINUTES OF EVIDENCE - VOLUME II (HC 515-II)